Steven & Alexandra Cohen Foundation
13
5
8
4
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
0.0%
0 terminated/withdrawn out of 13 trials
100.0%
+13.5% vs industry average
0%
0 trials in Phase 3/4
25%
1 of 4 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (13)
Transcranial Direct Current Stimulation for Post Treatment Lyme Disease
Role: collaborator
Psilocybin-Enhanced Psychotherapy for Methamphetamine Use Disorder
Role: collaborator
Ceftriaxone Pulse Dose for Post-Treatment Lyme Disease
Role: collaborator
Effects of Repeated Psilocybin Dosing in OCD
Role: collaborator
Psilocybin-Assisted Therapy for the Treatment of Cancer-Related Anxiety in Patients With Metastatic Cancer
Role: collaborator
A Study of Psilocybin for PTSD
Role: collaborator
A Second Psilocybin Group Therapy for the Treatment of Cancer-Related Anxiety in Partial Responders With Metastatic Cancer
Role: collaborator
PRoMiSS: Psilocybin and the Role of Music in Set and Setting
Role: collaborator
Effects of Psilocybin in Post-Treatment Lyme Disease
Role: collaborator
MDMA-assisted Cognitive Processing Therapy Versus Cognitive Processing Therapy for Veterans With Severe Posttraumatic Stress Disorder
Role: collaborator
Navigating Pregnancy and Parenthood With Lyme Disease
Role: collaborator
Group MDMA-therapy for Veterans With PTSD
Role: collaborator
Pregnancy and Early Neurodevelopmental Outcomes Following In Utero Lyme Disease Exposure
Role: collaborator
All 13 trials loaded